Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,367.00+0.23%ETH$2,446.24+1.16%GOLD$4,382.50-0.39%OIL$101.15-0.75%
Smart Investors Daily
Boundless Bio, Inc. logo

NASDAQ · BOLD

Boundless Bio, Inc.

Healthcare · Biotechnology

$2.82

Down-$0.02 (-0.71%)

Updated Sep 17, 2026, 11:55 PM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
25.74M
P/E ratio
-0.4
Dividend yield
0.00%
52-week range
$1.07 – $3.16
Volume
102.23K
Avg. volume
159.75K

Price performance

BOLD price history

1M range · 20 trading sessions · Daily adjusted prices

BOLD closed at $2.82 after 20 trading sessions, down 1.40% for the selected period.

Last close
$2.82
Period change
-1.40%
Period low
$2.81
Period high
$3.00
Daily close
View OHLC price history
BOLD OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$2.81$2.85$2.785$2.82102.23K
Sep 15, 2026$2.83$2.85$2.81$2.8123.23K
Sep 14, 2026$2.84$2.89$2.8399$2.8429.83K
Sep 11, 2026$2.85$2.85$2.81$2.8363.84K
Sep 10, 2026$2.85$2.87$2.82$2.8428.65K
Sep 9, 2026$2.86$2.8781$2.83$2.8548.82K
Sep 8, 2026$2.87$2.94$2.76$2.86168K
Sep 4, 2026$2.87$2.89$2.86$2.8720K
Sep 3, 2026$2.90$2.94$2.85$2.8772.44K
Sep 2, 2026$2.89$2.91$2.85$2.8981.53K
Sep 1, 2026$2.81$2.905$2.805$2.89146.03K
Aug 31, 2026$2.81$2.94$2.80$2.81103.24K
Aug 28, 2026$2.82$2.86$2.80$2.8375.54K
Aug 27, 2026$2.91$2.99$2.86$2.8646.67K
Aug 26, 2026$2.98$3.04$2.90$2.915158.8K
Aug 25, 2026$2.96$3.00$2.93$2.9441.26K
Aug 24, 2026$3.05$3.1636$2.905$2.96118.48K
Aug 21, 2026$2.91$3.02$2.91$3.00157.16K
Aug 20, 2026$2.84$3.01$2.84$2.90218.74K
Aug 19, 2026$2.89$2.935$2.80$2.8695.55K

Latest BOLD news

The latest Smart Investors Daily articles mentioning BOLD.

Stock researchCompany · Overview

BOLD research

Overview

Company profile and research snapshot.

Company profile

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.06
Implied upside
—
Analysts
—
BOLD recent ratings
DateFirmRatingTarget
Aug 11, 2025HC Wainwright & Co.Buy—
Jun 2, 2025HC Wainwright & Co.Buy—
May 28, 2025Leerink PartnersMarket Perform—
Dec 13, 2024GuggenheimNeutral—
Apr 22, 2024Leerink PartnersOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer

Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and continues to serve on the Board of Directors; Jerome Boyd-Kirkup, PhD, founding Chief Scientific Officer, transitions to Senior Scientific Advisor SAN DIEGO and SEATTLE and SINGAPORE, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a clinical-stage

Benzinga · Sep 9, 2026

Callio Therapeutics Appoints Zachary Hornby As CEO

Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancerPiers Ingram, PhD, Co-Founder, transitions to Senior Advisor and

Benzinga · Aug 10, 2026

Boundless Bio Q2 EPS $(1.06) Misses $(0.61) Estimate

Boundless Bio (NASDAQ:BOLD) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $(0.61) by 73.77 percent. This is a 51.43 percent decrease over losses of $(0.70) per share from

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By